"Time-resolved laser-induced fluorescence spectroscopy or TR-LIFS can be used to accurately identify plaque with these dangerous characteristics, while the plaque still lines the walls of vessels," said lead researcher Laura Marcu, Ph.D., director of biophotonics research at the Cedars-Sinai Medical Center and associate professor at the University of Southern California in Los Angeles.
The laser pulse heats up or "excites" molecules in the plaque while researchers measure the "time" that molecules stay in the excited state. This time is specific to different types of molecules, which helps researchers determine the "exact composition of the plaque."
When plaque has a thin, fibrous layer or cap over a large core area of lipids, it's most vulnerable to rupture, which can result in the blood supply to a part of the heart or brain being blocked.
Researchers tested the TR-LIFS device by identifying the type of plaque found in the carotid arteries, the main blood supply for the brain. They measured 353 plaque areas in the carotid arteries of 50 patients who were scheduled to undergo carotid endarterectomy, a procedure in which the carotid arteries are opened and plaque is surgically removed.
After the endarterectomy was done, pathologic examination was used to categorize the plaques as early (minimal thickening), fibrotic (collagen-rich lesions), or high-risk (necrotic core with a thin cap). These results were compared to those the researchers received when using the fluorescence spectroscopy to categorize the same plaques as early, fibrotic and high risk.
Results indicated the technique was 97 percent effective in identifying high-risk lesions.
"TR-LIFS was tested in patients undergoing endarterectomy because it allowed us to assess the plaque inside the artery and then compare our findings with the pathology of the specimens that had been surgically removed," Marcu said. "The study confirmed that our approach is feasible. The new method identifies the high-risk plaques, those with large lipid pools and inflammatory cells, factors contributing to weakening of the plaque. Plaques that do not display these characteristics are of less risk to the patient."
The initial results with TR-LIFS encouraged the researchers to develop an intravascular catheter-based system that would permit minimally invasive evaluation of arteries.
"The goal is to develop a TR-LIFS probe that can be used to assess plaque in vessels in the heart," Marcu said. "That's where TR-LIFS could be important. Plaque composition could dictate the best intervention: bare metal stenting, use of drug-eluting stents, balloon angioplasty or even bypass surgery to restore blood flow to the heart."
Co-authors are: Javier A. Jo, Ph.D.; Qiyin Fang, Ph.D.; Thanassis Papaioannou, M.S.; Jian-Hua Qiao, M.D.; Michael C. Fishbein, M.D.; J. Dennis Baker, M.D.; and Julie A. Freischlag, M.D.
Statements and conclusions of study authors that are published in the American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.